PD-1 Clinical Trials

42 recruitingLast updated: June 17, 2026

There are 42 actively recruiting pd-1 clinical trials across 2 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Guangzhou, Guangdong, China, Shanghai, Shanghai Municipality, China, Chengdu, Sichuan, China. Updated daily from ClinicalTrials.gov.


PD-1 Trials at a Glance

42 actively recruiting trials for pd-1 are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 22 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Chengdu. Lead sponsors running pd-1 studies include Sun Yat-sen University, Nanfang Hospital, Southern Medical University, and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

Browse pd-1 trials by phase

Treatments under study

About PD-1 Clinical Trials

Looking for clinical trials for PD-1? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PD-1 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PD-1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting
Phase 2

EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC

EGFR Activating MutationLung Cancer Non-Small Cell Cancer (NSCLC)PD-1 Antibody
Nanfang Hospital, Southern Medical University32 enrolled1 locationNCT07637448
Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Neoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy+1 more
Peking University People's Hospital80 enrolled1 locationNCT07359040
Recruiting
Phase 1

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

NSCLCLeptomeningeal MetastasisLow Dose Radiotherapy+1 more
Sichuan University10 enrolled1 locationNCT06431685
Recruiting

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

CancerPD-1Thyroid
Icahn School of Medicine at Mount Sinai17 enrolled1 locationNCT04615988
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University27 enrolled1 locationNCT07447570
Recruiting
Phase 1Phase 2

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)

ImmunotherapyAFP Gastric or Gastroesophageal Junction AdenocarcinomaPD-1/CTLA-4+1 more
Hebei Medical University Fourth Hospital39 enrolled1 locationNCT07289997
Recruiting
Phase 2

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial CarcinomaKidney PreservationHER-2 ADC+1 more
RenJi Hospital20 enrolled1 locationNCT05912816
Recruiting

Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics

Ulcerative Colitis (UC)Crohn Disease (CD)Autism Spectrum Disorder+6 more
Chen QiYi4,000 enrolled1 locationNCT07261826
Recruiting
Not Applicable

Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC

Non-small Cell Lung CancerElectroacupuncturePD-1 Inhibitors+1 more
Kong Fanming120 enrolled1 locationNCT07239661
Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252
Recruiting
Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Anti-PD-1 AntibodyChronic Hepatitis B
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05769816
Recruiting
Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Anti-PD-1 AntibodyChronic Hepatitis BPeg-IFNα
The Second Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT05771402
Recruiting
Phase 2

Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

Neoadjuvant TherapyPD-1 InhibitorUpper Tract Urothelial Carcinoma+1 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07126119
Recruiting
Phase 2

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Neoadjuvant TherapyTislelizumabPD-1 Inhibitor+3 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07125547
Recruiting
Not Applicable

Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC

Non-small Cell Lung CancerElectroacupunctureElderly Patients (>65 Years)+1 more
Kong Fanming120 enrolled1 locationNCT07086300
Recruiting
Phase 1

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Gastrointestinal TumorsPersonalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Ruijin Hospital40 enrolled1 locationNCT07067385
Recruiting
Phase 2

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

ChemotherapyPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University208 enrolled3 locationsNCT06811844
Recruiting
Phase 1

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer (CRC)PD-1Tumor Infiltrating Lymphocytes
Ruijin Hospital29 enrolled1 locationNCT07035002
Recruiting

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Nanfang Hospital, Southern Medical University20 enrolled1 locationNCT06327178